Venkatesh Ravi, MD
Clinical Cardiac Electrophysiology · Tulsa, OKNPI 1821438227
Payments from drug & device makers
What this record shows
The money is spread across several categories — grants (59.1%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. 31 manufacturers reported payments, led by Boston Scientific at 39.8% of the total. Reporting peaked in 2020 at $14,714 and has fallen 92.6% since, to $1,088 in 2025.
Across 166 payments — averaging $189.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$13K
- Medtronic$12K
- Biotronik Inc.$3K
- Abbott$2K
- Biosense Webster, Inc.$777
- Baylis Medical Company Inc$242
- plus $1K from 25 others
What the payments were for
- Grants$18,57859%
- Travel & lodging$6,49721%
- Food & beverage$5,59218%
- Education$7822%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 17 | $12,502 |
| Medtronic(2 entities) | 45 | $12,042 |
| Biotronik Inc. | 15 | $2,879 |
| Abbott | 15 | $1,697 |
| Biosense Webster, Inc. | 15 | $777 |
| Baylis Medical Company Inc | 1 | $242 |
| Amgen | 5 | $186 |
| Johnson & Johnson | 10 | $171 |
| Medical Device Business Services, Inc. | 1 | $129 |
| Cardiovascular Systems Inc. | 1 | $103 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $83 |
| Pfizer | 5 | $72 |
| Novartis | 4 | $62 |
| Boehringer Ingelheim | 4 | $59 |
| Amarin Pharma, Inc. | 3 | $46 |
| Abiomed | 1 | $44 |
| Vivaquant Inc, Dba Rhythm Express | 1 | $42 |
| Angiodynamics, Inc. | 2 | $39 |
| Sanofi-aventis U.S. LLC | 2 | $37 |
| Philips North America LLC | 2 | $34 |
| Bayer | 2 | $32 |
| Kestra Medical Technology Services, Inc. | 1 | $23 |
| Bard Peripheral Vascular, Inc. | 1 | $20 |
| Baxter Healthcare | 1 | $20 |
| Cardiva Medical, Inc. | 1 | $18 |
| Actelion Pharmaceuticals US, Inc. | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Novo Nordisk | 1 | $16 |
| AstraZeneca | 1 | $15 |
| Chiesi USA, Inc. | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL BRADY$10,000
- GENERAL - THERAPIES$2,240
- Rivacor$1,770
- Edora$1,770
- Acticor$1,770
- BioMonitor$998
- Solia$998
- Ensite Cardiac Mapping System$875
- Micra$794
- Plexa$772
- Sentus$772
- AVEIR$423
- Carto 3$260
- NRG needle$242
- Cobalt$169
- Repatha$117
- Coronary Orbital Atherectomy System$103
How this compares
$31,450 in reported general payments places this provider in the 65th percentile of 30 clinical cardiac electrophysiology providers in Oklahoma.
See all clinical cardiac electrophysiology providers in Oklahoma →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 248 | $215,778 |
| XareltoRivaroxaban | 25 | $29,315 |
| EntrestoSacubitril/Valsartan | 13 | $19,874 |
| MultaqDronedarone Hcl | 17 | $12,940 |
| Flecainide Acetate | 110 | $4,464 |
| Metoprolol Succinate | 198 | $2,924 |
| Amiodarone Hcl | 86 | $1,985 |
| Digoxin | 19 | $631 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 15 | $591 |
| Metoprolol Tartrate | 87 | $569 |
| Carvedilol | 48 | $516 |
| Nadolol | 12 | $484 |
| Potassium Chloride | 17 | $353 |
| Amlodipine Besylate | 18 | $224 |
| Losartan Potassium | 12 | $189 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $72 | $215,778248 claims |
| Johnson & JohnsonXarelto | $171 | $29,31525 claims |
| NovartisEntresto | $62 | $19,87413 claims |
| Sanofi-aventis U.S. LLCMultaq | $37 | $12,94017 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 30 clinical cardiac electrophysiology providers in Oklahoma.
Other clinical cardiac electrophysiology in Tulsa
- David SandlerTulsa$86K
- Craig CameronTulsa$52K
- Vikram KatariTulsa$34K
- James ComanTulsa$24K
- Joseph GardTulsa$23K
- Ele WuTulsa$22K
- Andrew HinojosTulsa$17K
- David OkadaTulsa$16K
- Warren JackmanOklahoma City$2.3M
- Sunny PoOklahoma City$260K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.